Promiximab
Promiximab is a humanized anti-CD56 IgG1 monoclonal antibody with a Kd value of 0.78 pM against the human target. Promiximab specifically binds to CD56-positive small cell lung cancer (SCLC) cells, possesses antiproliferative activity, and induces tumor regression. Promiximab serves as the antibody component of the antibody-drug conjugates Promiximab-DUBA and Promiximab-MMAE. Promiximab can be used in studies related to small cell lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2924882-34-6
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H526 | IC50 |
> 300 nM
|
Inhibition of cell viability against human NCI-H526 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
Inhibition of cell viability against human NCI-H526 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
|
29435172 |
| NCI-H524 | IC50 |
> 300 nM
|
Inhibition of cell viability against human NCI-H524 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
Inhibition of cell viability against human NCI-H524 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
|
29435172 |
| NCI-H69 | IC50 |
> 300 nM
|
Inhibition of cell viability against human NCI-H69 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
Inhibition of cell viability against human NCI-H69 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
|
29435172 |
In Vitro
Promiximab (0.02-1200 nM; 72 h) does not inhibit the viability of CD56-expressing small cell lung cancer (SCLC) cell lines NCI-H526, NCI-H524, NCI-H69, or human NK cells at concentrations up to 1200 nM[1].
Promiximab (1 μg/mL; 30 min) specifically binds to CD56-expressing small cell lung cancer (SCLC) cell lines NCI-H526, NCI-H524 and NCI-H69, but does not bind to CD56-negative SCLC cell lines NCI-H446 and NCI-H128[1].
Promiximab (1 μg/mL; 4 h) binds to both glycosylated and deglycosylated CD56 ECD, and cross-reacts with human CD56-expressing cells[1].
Promiximab (10 μg/mL; 30 min, 3 h) is efficiently internalized into CD56-expressing small cell lung cancer (SCLC) cell lines NCI-H526, NCI-H524 and NCI-H69[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SCLC cell lines NCI-H526, NCI-H524, NCI-H69, human NK cells
-
Concentration:0.02, 0.07, 0.29, 1.17, 4.69, 18.75, 75, 300, 1200 nM
-
Incubation Time:72 h
-
Result:Showed no significant inhibitory effect on cell viability.
In Vivo
Promiximab (5-10 mg/kg; i.v.; every three days; 3 total doses) causes no visible histopathological toxicity to major organs in Balb/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude (female, 5-6 weeks old, subcutaneous xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; every three days; 3 total doses
-
Result:Allowed tumors to grow to approximately 2000 mm3 over the study period.
Maintained stable body weight throughout treatment.
-
Animal Model:Balb/c[1]
-
Dosage:5, 10 mg/kg
-
Administration:i.v.; every three days; 3 total doses
-
Result:Showed no obvious histopathological changes in heart, liver, spleen, lung, and kidney tissues compared to vehicle-treated controls.
Chemical Information
-
CAS No. 2924882-34-6
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Promiximab Related Classifications
HY-P992523 Related Classifications
Powered by Bioz